Biomerica, Inc.

📍 Irvine, United States🗓 Founded 1971👥 50 employees💰 Last funded 2021
Biomerica, Inc. (www.biomerica.com) is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and in physicians’ offices) and in hospital/clinical laboratories for the early detection of medical conditions and diseases. The Company’s products are designed to enhance health and well-being, while reducing total healthcare costs. Biomerica primarily focuses on products for Gastrointestinal Disease, Diabetes and esoteric testing. The Biomerica InFoods® IBS product identifies patient specific foods that when removed may alleviate an individuals IBS symptoms. This patent pending diagnostic guided therapy is designed to allow for a patient specific guided dietary regimen to improve Irritable Bowel Syndrome (IBS) outcomes. The point-of-care product is being developed to allow physicians to perform the test in-office using a finger stick blood sample while a clinical lab version of the product will be the first for which the company will seek regulatory approval. A billable CPT code that can be used by both clinical labs and physicians​ offices is available for InFoods® diagnostic products. Since the InFoods® product is a diagnostic guided therapy and not a drug, it has no drug type side effects.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
1971
Founded
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Biomerica, Inc.?
Biomerica, Inc. has 1 investors on record on gritt.io.
When did Biomerica, Inc. last raise funding?
The most recent investment in Biomerica, Inc. recorded on gritt.io was in 2021.
When was Biomerica, Inc. founded?
Biomerica, Inc. was founded in 1971.
What industry is Biomerica, Inc. in?
Biomerica, Inc. operates in Medical Equipment Manufacturing. Find similar Medical Equipment Manufacturing investors on gritt.io.
Where is Biomerica, Inc. based?
Biomerica, Inc. is headquartered in Irvine, United States.